etravirine has been researched along with tolbutamide in 2 studies
| Studies (etravirine) | Trials (etravirine) | Recent Studies (post-2010) (etravirine) | Studies (tolbutamide) | Trials (tolbutamide) | Recent Studies (post-2010) (tolbutamide) |
|---|---|---|---|---|---|
| 572 | 90 | 321 | 5,368 | 238 | 265 |
| Protein | Taxonomy | etravirine (IC50) | tolbutamide (IC50) |
|---|---|---|---|
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.392 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, FE; Clercq, E; Hao, QQ; Ling, X; Pannecouque, C | 1 |
1 review(s) available for etravirine and tolbutamide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for etravirine and tolbutamide
| Article | Year |
|---|---|
Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
Topics: Animals; Anti-HIV Agents; HIV Reverse Transcriptase; HIV-1; Mice; Molecular Docking Simulation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2022 |